Conclusion
We have demonstrated that JAK1 is a possible therapeutic target for
severe corticosteroid-resistant asthma with airway eosinophilia and
persistent Th2-type inflammation, and that ruxolitinib has potential as
an alternative pharmacotherapy. (249 words)